Non-Addictive Pain Gene Therapy Breakthrough | UPenn
UPenn researchers unveil gene therapy targeting ACC neurons for morphine-like pain relief minus addiction. Preclinical success in mice paves way for safer chronic pain management.
No reviews yet. Be the first to rate Gregory!
Gregory Corder is Assistant Professor of Psychiatry in the Department of Psychiatry at the Perelman School of Medicine, University of Pennsylvania. He earned a B.S. in Cell and Molecular Biology from Tulane University in 2007 and a Ph.D. in Physiology from the University of Kentucky in 2013. He completed postdoctoral training in the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University from 2013 to 2018.
Dr. Corder is a neuroscientist and pain researcher whose work focuses on the neural basis of pain perception, the emergence of pain and motivated behaviors from neural circuit activity, and pathological changes in brain networks that drive chronic pain and opioid dependence. His research integrates in vivo calcium imaging, optogenetics, viral tool development, single-nuclei RNA sequencing, neuroanatomical tracing, and deep-learning behavior modeling in preclinical rodent models. The Corder Lab develops activity-dependent genetic tools, next-generation circuit-based therapies, and non-opioid analgesic strategies, including gene therapies for chronic pain. Selected publications include “Exogenous and endogenous opioids in pain” (Annual Review of Neuroscience, 2018) and “Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia” (Nature Medicine, 2017). He maintains graduate group affiliations in Neuroscience and Pharmacology.
UPenn researchers unveil gene therapy targeting ACC neurons for morphine-like pain relief minus addiction. Preclinical success in mice paves way for safer chronic pain management.